42 studies found for:    "Anthrax"
Show Display Options
Rank Status Study
21 Recruiting Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions: Infection;   Hypertension;   Anesthesia;   Pain;   Reflux;   Nausea;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure)
Intervention: Drug: Ampicillin
22 Completed CDC Anthrax Vaccine Clinical Trial
Condition: Healthy
Intervention: Biological: BioThrax or Anthrax Vaccine Adsorbed
23 Completed A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
24 Active, not recruiting Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Other: IV Ciprofloxacin;   Other: Oral Ciprofloxacin
25 Active, not recruiting Safety, Tolerability and PK of Repeat Administration of IV ETI-204
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
26 Recruiting Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
27 Completed VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Conditions: Smallpox;   Anthrax
Intervention: Behavioral: BioCASES and BioTESTS
28 Terminated Ph1 Study of Valortim and Doxycycline in Humans
Condition: Anthrax
Interventions: Drug: Doxycycline and Valortim;   Drug: Placebo Antibiotic and Valortim;   Drug: Placebo Antibiotic and Placebo Valortim
29 Completed Ciprofloxacin BioThrax Co-Administration Study
Condition: Anthrax
Interventions: Biological: BioThrax;   Drug: Ciprofloxacin
30 Completed Placebo-Controlled, Sequential Group, Single Dose, Dose-Escalation Study to Evaluate the Safety and PK of ETI-204
Condition: Anthrax
Interventions: Drug: ETI-204, "Anthim";   Drug: placebo
31 Completed
Has Results
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Condition: Anthrax
Intervention: Biological: BioThrax
32 Completed Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Condition: Anthrax
Interventions: Drug: AVP-21D9;   Drug: Placebo
33 Completed Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Condition: Anthrax
Interventions: Drug: Normal Saline for Injection;   Biological: MDX1303
34 Suspended Ph1 Study of Valortim and Ciprofloxacin in Humans
Condition: Anthrax
Interventions: Drug: Ciprofloxacin and Valortim;   Drug: Placebo Antibiotic and Valortim;   Other: Placebo Antibiotic and Placebo Valortim
35 Completed
Has Results
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Condition: Therapeutic Treatment of Inhalation Anthrax
Intervention: Biological: Raxibacumab
36 Recruiting BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Conditions: Pregnancy Complications;   Pregnancy Outcome;   Congenital Abnormalities
Intervention: Biological: Observational Intervention
37 Recruiting A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
Conditions: Safety;   Tolerability;   Reactogenicity
Intervention: Biological: PA83-FhCMB
38 Completed
Has Results
Glyburide Advantage in Malignant Edema and Stroke Pilot
Condition: Ischemic Stroke
Intervention: Drug: RP-1127 (Glyburide for injection)
39 Completed A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: HIV Infections
Intervention: Biological: HIV LFn-p24
40 Completed Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
Condition: Infection
Intervention: Drug: Ciprofloxacin (BAYQ3939)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-42) Show next page of results
Indicates status has not been verified in more than two years